Campbell & Co Investment Adviser’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-90,977
Closed -$2.27M 1341
2025
Q4
$2.27M Sell
90,977
-41,547
-31% -$1.05M 0.11% 290
2025
Q3
$3.38M Buy
132,524
+118,192
+825% +$2.92M 0.26% 82
2025
Q2
$347K Sell
14,332
-43,434
-75% -$1.01M 0.02% 910
2025
Q1
$1.46M Buy
57,766
+50,176
+661% +$1.31M 0.11% 283
2024
Q4
$201K Sell
7,590
-74,906
-91% -$2.03M 0.02% 968
2024
Q3
$2.39M Buy
+82,496
New +$2.41M 0.18% 145
2024
Q2
Sell
-41,400
Closed -$1.15M 1281
2024
Q1
$1.15M Buy
+41,400
New +$1.15M 0.1% 337
2023
Q1
Sell
-7,812
Closed -$400K 983
2022
Q4
$400K Sell
7,812
-847
-10% -$40.6K 0.1% 418
2022
Q3
$379K Buy
+8,659
New +$421K 0.09% 403
2021
Q4
Sell
-19,550
Closed -$841K 768
2021
Q3
$841K Buy
19,550
+8,550
+78% +$379K 0.27% 94
2021
Q2
$431K Buy
+11,000
New +$428K 0.18% 197
2020
Q1
Sell
-13,173
Closed -$490K 376
2019
Q4
$490K Buy
+13,173
New +$469K 0.15% 238
2014
Q1
Sell
-242,073
Closed -$7.04M 277
2013
Q4
$7.04M Buy
+242,073
New +$7.05M 1.58% 4

Other funds holding PFE

Campbell & Co Investment Adviser's PFE Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Pfizer (PFE) in Q1 2026, closing a stake of 90,977 shares — an estimated $2.27M sold.

Campbell & Co Investment Adviser first reported a position in PFE in Q4 2013 and held it in 13 quarters. The position peaked at $7.04M in Q4 2013. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Campbell & Co Investment Adviser reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 90,977 Pfizer shares in Q1 2026, an estimated $2.27M.
  • Campbell & Co Investment Adviser first reported a position in Pfizer in Q4 2013 and held it in 13 quarters.
  • Campbell & Co Investment Adviser's Pfizer position peaked at $7.04M in Q4 2013.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.